1202-39-7

Basic information

• Product Name: 3,4-Dichlorocinnamic acid
• Synonyms: 3,4-DICHLOROCINNAMIC ACID, 97%, PREDOMIN ANTLY TRANS;3,4-DICHLOROCINNAMIC ACID 97%;3-(3,4-Dichlorophenyl)propenoic acid;3,4-Dichlorobenzeneacrylic acid;(2E)-3-(3,4-dichlorophenyl)acrylic acid;2-propenoic acid, 3-(3,4-dichlorophenyl)-, (2E)-;Cinnamic acid, 3,4-dichloro-;Nsc518800
• CAS NO: 1202-39-7
• Molecular Formula: C₉H₆Cl₂O₂
• Molecular Weight: 217.05
• EINECS: 214-866-4
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives;Cinnamic acid;C9;Carbonyl Compounds;Carboxylic Acids
• Mol File: 1202-39-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 218-220 °C(lit.)
• Boiling Point: 366.6 °C at 760 mmHg
• Flash Point: 175.5 °C
• Appearance: White to off-white/Powder or Crystalline Powder
• Density: 1.457 g/cm³
• Vapor Pressure: 5.07E-06mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: ethanol: soluble25mg/mL, very slightly hazy, faintly yellow
• PKA: 4.18±0.10(Predicted)
• BRN: 1872129
• CAS DataBase Reference: 3,4-Dichlorocinnamic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dichlorocinnamic acid(1202-39-7)
• EPA Substance Registry System: 3,4-Dichlorocinnamic acid(1202-39-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-24/25
• WGK Germany: 3
• RTECS: UD3333900
• HazardClass: IRRITANT
• Hazardous Substances Data: 1202-39-7(Hazardous Substances Data)

Usage

Description

3,4-Dichlorocinnamic acid is an organic compound characterized by its white powder form. It is known for its chemical property of undergoing photodimerization when exposed to water.

Uses

Used in Pharmaceutical Industry:
3,4-Dichlorocinnamic acid is used as a key intermediate in the synthesis of indolopiperidine CCR2B receptor antagonists. These antagonists are designed with a conformationally restricted C-5 linker chain and a restricted piperidine ring, which contribute to their effectiveness in targeting specific receptors.
The application of 3,4-Dichlorocinnamic acid in this context is significant due to its role in the development of potential therapeutic agents that can modulate the activity of CCR2B receptors, which are involved in various biological processes and diseases.

InChI:InChI=1/C9H6Cl2O2/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5H,(H,12,13)/b4-2+

Upstream product

• 141-82-2 malonic acid 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Downstream Products

• 77261-95-1 2-(3,4-Dichloro-phenyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 
• 40950-94-5 3-(3,4-dichloro-phenyl)-acrylic acid ethyl ester 
• 39156-98-4 3-(3,4-dichlorophenyl)acryloyl chloride 
• 20850-12-8 3,4-Dichlor-cinnamylchlorid 
• 56984-70-4 3-(3,4-dichlorophenyl) prop-2-en-1-ol 
• 25173-68-6 3(3,4-dichlorophenyl)propanoic acid 

Relevant articles and documents

Enantioselective Synthesis of N?H-Free 1,5-Benzothiazepines

An enantioselective sulfa-Michael-cyclization reaction was developed for the synthesis of 1,5-benzothiazepines with versatile pharmacological activities. The reaction between 2-aminothiophenol and α,β-unsaturated pyrazoleamides gave direct access to N?H-free 1,5-benzothiazepines in the presence of a chiral N,N′-dioxide/Yb(OTf)3complex. Excellent enantioselectivities (up to 96 % ee) and high yields (up to 99 %) were obtained for a broad range of substrates under mild reaction conditions. This method provided a facile approach to the antidepressant drug (R)-(?)-Thiazesim.

Synthesis and Antileukemic Activity of Bismethyl>-Substituted Pyrroloisoquinolines, Pyrroloquinolines, Pyrroloisobenzazepines, and Pyrrolobenzazepines

A series of bismethyl>-substituted pyrrole-fused tricyclic heterocycles were synthesized by using 1,3-dipolar cycloaddition reactions with a trifluoromethanesulfonate salt of an appropriate Resissert compound or with a mesoionic oxazolone intermediate.All of the bis(carbamates) were active in vivo against P388 lymphocytic leukemia with 5,6-dihydro-8-methoxy-1,2-bis(hydroxymethyl)pyrroloisoquinoline bis (3c) showing the highest level of activity.